|
Dennis Podlesak became a member of our board of directors in April 2006. Mr. Podlesak is the chief executive officer and a member of the board of directors of Cerexa Pharmaceutical which was spun out of Peninsula Pharmaceuticals where he was also the chief executive officer and where he led the sale of Peninsula to Johnson & Johnson. Cerexa is an innovation-driven biopharmaceutical company focused on infectious disease. Prior to Peninsula, Mr. Podlesak served as senior vice president and head of a North American Business Unit for Novartis AG and as a member of Novartis’ pharmaceutical executive committee and global leadership team. Earlier in his career, Mr. Podlesak served as vice president and head of the CEC division of Allergan, Inc. and as member of Allergan’s North American and global management team. Mr. Podlesak spent the first ten years of his career with SmithKline Beecham (now GlaxoSmithKline plc) where he was promoted to eight positions of increasing responsibility during his tenure with the company. Mr. Podlesak is a director of Avanir Pharmaceuticals, and Prevent Blindness, a non-profit organization that focuses on preventable blindness with a particular emphasis on children. Mr. Podlesak holds an M.B.A. from Pepperdine University and a B.A. in Business Administration from Western Illinois University. | 